Citi Reiterates Sell Rating on Sage Therapeutics (SAGE)
Tweet Send to a Friend
Citi analyst David Hoang reiterated a Sell rating and $8.00 price target on Sage Therapeutics (NASDAQ: SAGE).The analyst commented, "SAGE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


